All In Biotech

Drug Trial Radar · NCT01201356

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Apr 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,125

Actual

Start

Sep 13, 2010

Primary completion

Oct 19, 2018

Study completion Oct 19, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.

Conditions

  • Relapsing Forms of Multiple Sclerosis

Interventions

  • FingolimodDrug

    0.5 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and DeathTime frame: Baseline (Part I) to Month 6 Follow-up (Part II), up to 8 years

Locations

458 sites in 38 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Cullman, Alabama

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Maitland, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Sunrise, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Vero Beach, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Kansas City, Kansas

  • Novartis Investigative Site

    Lenexa, Kansas

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Kansas City, Missouri

  • Novartis Investigative Site

    Lebanon, New Hampshire

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Durham, North Carolina

  • Novartis Investigative Site

    Raleigh, North Carolina

  • Novartis Investigative Site

    Toledo, Ohio

  • Novartis Investigative Site

    Oklahoma City, Oklahoma

  • Novartis Investigative Site

    Tulsa, Oklahoma

  • Novartis Investigative Site

    Tualatin, Oregon

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Bristol, Tennessee

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Burlington, Vermont

  • Novartis Investigative Site

    Charlottesville, Virginia

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Salta, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Capital Federal, Buenos Aires, Argentina

Showing 40 of 458 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.